Intranasal administration of ketamine to treat depression

US9592207B2 · kind B2 · utility

Assignees

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US
• Yale University · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Dennis S. Charney · New York, US
• Sanjay J. Mathew · New York, US
• Husseini K. Manji · Rockville, US
• Carlos A. Zarate · Rockville, US
• John H. Krystal · Woodbridge, US

Key dates

• Filing date: Jun 17, 2014
• Grant date: Mar 14, 2017
• Expiry date: Jun 17, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).